These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27940205)

  • 1. Re-calculating! Navigating through the osteosarcoma treatment roadblock.
    McGuire J; Utset-Ward TJ; Reed DR; Lynch CC
    Pharmacol Res; 2017 Mar; 117():54-64. PubMed ID: 27940205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteosarcoma: review of the past, impact on the future. The American experience.
    Jaffe N
    Cancer Treat Res; 2009; 152():239-62. PubMed ID: 20213394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.
    Harrison DJ; Schwartz CL
    Curr Treat Options Oncol; 2017 Apr; 18(4):24. PubMed ID: 28391422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs in early clinical development for the treatment of osteosarcoma.
    Heymann MF; Brown HK; Heymann D
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs.
    Kleinsimon S; Kauczor G; Jaeger S; Eggert A; Seifert G; Delebinski C
    BMC Complement Altern Med; 2017 Jan; 17(1):26. PubMed ID: 28061770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
    Meazza C; Cefalo G; Massimino M; Daolio P; Pastorino U; Scanagatta P; Morosi C; Podda M; Ferrari A; Terenziani M; Spreafico F; Casanova M; Parafioriti A; Collini P; Gandola L; Bastoni S; Biassoni V; Schiavello E; Chiaravalli S; Puma N; Bergamaschi L; Luksch R
    Med Oncol; 2017 Nov; 34(12):191. PubMed ID: 29094224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
    Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
    Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.
    Guiho R; Biteau K; Heymann D; Redini F
    Future Oncol; 2015; 11(3):535-42. PubMed ID: 25675131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
    Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
    Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
    Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
    Meyers PA
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1035-49. PubMed ID: 19671023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
    Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
    Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can survival be improved in localized osteosarcoma?
    Jeon DG; Song WS
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1313-25. PubMed ID: 20735316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future therapeutic approaches for osteosarcoma.
    Harrison DJ; Geller DS; Gill JD; Lewis VO; Gorlick R
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):39-50. PubMed ID: 29210294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.